Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

November 4, 2025 6:45 AM EST

Focused Execution Delivers Strong EPS Performance Landmark Agreement Reached with U.S. Government Provides Longer-Term Business Clarity Secured Early FTC Clearance for Proposed Metsera Acquisition to Meaningfully Compete in Obesity

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of Pfizer:

I am proud of Pfizers... More